Cypress Bioscience Test Gets Positive Medicare Reimbursement Decision | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cypress Bioscience said that it has received a positive coverage determination from a Medicare administrator for its testing service aimed at helping physicians prescribe a rheumatoid arthritis therapy.

The San Diego-based firm said that Palmetto GBA, an administrator for Medicare Part B in California, issued the positive coverage determination for its Avise PG testing service. The testing service helps physicians make decisions regarding methotrexate therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.